EL7.AI
StocksMediumUpdated×2•Originally published 29 July 2026•Updated 29 July 2026•
1 min read

Humana Details $908M MaxHealth Acquisition and Q2 EPS as Constellium Hits Record

Key Facts

1Humana reported its Q2 2026 financial results and reaffirmed its adjusted financial guidance for the full year 2026.
2Constellium reported record Segment Adjusted EBITDA for Q2 2026 and raised its full-year 2026 guidance.

As the quarterly earnings season continues to shape investor sentiment, Humana has disclosed significant strategic moves in its Q2 2026 results, including the completion of its MaxHealth acquisition for approximately $908 million. The insurer reported diluted earnings per share of $5.73 for the quarter ended June 30, 2026, with net income reaching $694 million. This performance was underpinned by Medicare Advantage care costs remaining within expectations, allowing the company to reaffirm its full-year financial guidance.

Per market data, HUM shares closed at $388.71 and CSTM at $29.08 on July 28, 2026, with Humana showcasing a robust liquidity position including a $5.0 billion revolving borrowing capacity and $1.32 billion in outstanding commercial paper. Meanwhile, Constellium raised its 2026 outlook following record Segment Adjusted EBITDA, driven by favorable price-mix and metal costs that outperformed broader industrial sector trends.

Looking ahead, traders are watching support levels for HUM near $371.50, while CSTM faces resistance at the $29.50 level (as of July 28, 2026 close). With no major catalysts in the economic calendar for the next seven days, market attention will focus on Humana's integration of the MaxHealth assets and Constellium's ability to deliver on its raised free cash flow targets exceeding $300 million.